T
Tvardi Therapeutics, Inc. (TVRD)
NCM – Real Time Price. Currency in USD
3.98
+0.02 (0.51%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.98
+0.02 (0.51%)
At close: May 12, 2026, 4:00 PM EDT
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
| Name | Position |
|---|---|
| Dr. Imran Alibhai Ph.D. | CEO & Director |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of R&D |
| Dr. John Kauh M.D. | Chief Medical Officer |
| Dr. Michael T. Lewis Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Ronald A. DePinho M.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Yixin Chen Ph.D. | Vice President of CMC |
| Mr. Dan Conn J.D., M.B.A. | CFO & Corporate Secretary |
| Mr. David J. Tweardy M.D. | Co-Founder & Scientific Advisory Board Member |
| Mr. Stephen O'Brien CPA | VP of Finance & Corporate Controller |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | POS AM | tm269412-2_posam.htm |
| 2026-05-08 | 8-K | tm2613977d1_8k.htm |
| 2026-05-01 | S-3 | tm2613101-1_s3.htm |
| 2026-04-23 | DEFA14A | tm266756d2_defa14a.htm |
| 2026-04-01 | POS EX | tm2610047d2_posex.htm |
| 2026-03-31 | 10-K | tvrd-20251231x10k.htm |
| 2026-03-06 | 8-K | tm268178d1_8k.htm |
| 2026-01-16 | 8-K | tm263373d1_8k.htm |
| 2025-12-18 | 8-K | tm2533917d1_8k.htm |
| 2025-11-19 | 8-K | tm2531635d1_8k.htm |